Description

Watch this EASL Studio to find out:

• Which policies for prioritisation exist within a deceased donor liver allocation system?
• What is the impact of novel cancer therapies on the selection of patients with prior cancer?

Faculty

• Prof. Sherrie Bhoori (Moderator)
• Prof. Pål-Dag Line (Faculty)
• Prof. Vincenzo Mazzaferro (Faculty)
• Prof. Gonzalo Sapisochin (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

In this JHEP Live the faculty discuss the use of antisense oligonucleotides and siRNAs in the treatment of chronic hepatitis B infections.

Faculty

• Prof. Joerg Petersen (Moderator)
• Prof. Maria Buti (Faculty)
• Prof. Man-Fung Yuen (Faculty)

Articles of interest

• Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB
• N-acetyl galactosamine-conjugated antisense oligonucleotide (GSK3389404) in chronic hepatitis B patients on stable nucleos(t)ide therapy: Phase 2a, randomised, double-blind, controlled study

Related episodes

• Treatment of HBV-HDV coinfection in the era of entry inhibition
• JHEP Live: Stop Nuc in HBeAg negative patients
• Midday Talks: HBV and HDV drug development – Where do we stand and where are we going?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

This EASL Studio episode focuses on the pathogenesis and treatment options of the cholestatic pruritus.

Faculty

• Prof. Verena Keitel (Moderator)
• Prof. Andreas Kremer (Faculty)
• Dr Binita Kamath (Faculty)
• Prof. Ronald Oude Elferink (Faculty)

Related episodes

• New treatment options for hereditary cholestasis syndromes: A game-changer?
• Primary biliary cholangitis: A look at the future therapy landscape for patients

This EASL Studio has been sponsored by GSK and Mirum Pharmaceuticals. The sponsors have had no editorial control over the content featured.

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Currently, the only established therapeutic option for end-stage liver disease is orthotopic liver transplantation. However, the paucity of donor organs limits this option to only a few patients. From liver stem cells to advanced tissue bioengineering, this episode of EASL Studio discusses regenerative hepatology techniques as an alternative treatment for patients.

Faculty

• Prof. Pedro Baptista (Moderator)
• Prof. Tobias Cantz (Faculty)
• Prof. Karen Piper Hanley (Faculty)
• Prof. Frederic Lemaigre (Faculty)

Related episode:

• YI Choice: Propelling liver cell biology into the third dimension

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Traditionally, journal impact factor has been the way to measure the impact of ones scientific articles. However, social media platforms are increasingly being used for the dissemination of publications. Join the faculty as they debate novel metrics to measure the impact of articles.

Faculty

• Prof. Jesus Banales (Moderator)
• Dr Atoosa Rabiee (Faculty)
• Dr Elliot Tapper (Faculty)
• Dr Juan Turnes (Faculty)

Related episode

• New era for science dissemination: The role of social media

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

As we near the end of 2022, this EASL Studio reflects upon:

• Which topics were most published about
• Which fields will we focus on in 2023
• What will the future of hepatology look like?

Faculty

• Prof. Paolo Angeli (Moderator)
• Prof. Jessica Zucman-Rossi (Moderator)
• Prof. Thomas Berg (Faculty)
• Prof. Aleksander Krag (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

In this episode of EASL Studio the experts discuss a non-cirrhotic portal vein thrombosis (PVT):

• What is PVT in the absence of cirrhosis,
• The role of interventional radiology in the management of portal cavernoma, and
• An update from the VALDIG portal Vein Thrombosis meeting

Faculty

• Prof. Pierre-Emmanuel Rautou (Moderator)
• Prof. Juan-Carlos Garcia-Pagan (Faculty)
• Dr Aurélie Plessier (Faculty)

Related article: Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis, Plessier et al. – NEJM Evidence – 2022

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Results from current clinical trials are rapidly evolving, with mixed results. In this EASL Studio the faculty discuss:

• why certain trials have failed whereas others have succeeded,
• what we have learned about the connection between overall survival and progression-free survival as endpoints, and
• how the systemic therapy of HCC has evolved.

Faculty

• Prof. Peter Galle (Moderator)
• Prof. Bruno Sangro (Faculty)
• Dr Anna Saborowski (Faculty)
• Prof. Arndt Vogel (Faculty)

Related episodes

• S2E15 – JHEP Live – The best animal model for HCC — lost in translation
• Special Edition: Highlights of the Liver Cancer Summit 2022
• Policy Dialogues Episode 3: Liver Cancer: The risk of ignorance

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

The value of scientific collaboration and data sharing through registries and consortia is unequivocal. But what are the main challenges to building a consortium and how do we overcome them.

Join the faculty as they provide you with a practical, experience-based view of how to build a successful consortium.

Faculty

• Dr Marta Afonso (Moderator)
• Dr Mattias Mandorfer (Moderator)
• Prof. Jesús Bañales (Faculty)
• Prof. Rajiv Jalan (Faculty)
• Prof. Pierre Emmanuel Rautou (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.